Nanobiotix Announces Preliminary €75M Global Offering of Shares and Warrants

summarizeSummary

Nanobiotix announced a preliminary €75 million global offering of ordinary shares and pre-funded warrants to fund its development programs, which is expected to cause substantial dilution.

check_boxKey Events

• Preliminary Global Offering Announced

  Nanobiotix is conducting a preliminary global offering to raise €75 million through the sale of ordinary shares (including ADSs) and pre-funded warrants.

• Substantial Dilution Expected

  The offering is expected to result in substantial and immediate dilution for existing shareholders.

• Funds for Development and Runway Extension

  Proceeds will accelerate development of JNJ-1900 and Nanoprimer platforms, and extend the company's cash runway beyond early 2028.

• Positive Clinical Context

  The capital raise occurs amidst recent positive clinical data for JNJ-1900, including promising Part 1 data from the CONVERGE study and an accelerated readout for the pivotal Phase 3 NANORAY-312 trial.

auto_awesomeAnalysis

Nanobiotix has filed a preliminary prospectus supplement for a global offering aiming to raise €75 million through the sale of ordinary shares (including ADSs) and pre-funded warrants. This capital raise is substantial, representing approximately 3.7% of the company's market capitalization, and is expected to result in immediate dilution for existing shareholders. The proceeds are intended to accelerate development programs for JNJ-1900 and Nanoprimer platforms, and for general corporate purposes. This offering follows recent positive clinical data announcements, suggesting the company is leveraging positive momentum to secure funding for future growth and extend its cash runway beyond early 2028.